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Abstract 1 
To replicate the double stranded human papillomavirus 16 (HPV16) DNA genome viral proteins E1 and 2 
E2 associate with the viral origin of replication, E2 can also regulate transcription from adjacent 3 
promoters. E2 interacts with host proteins in order to regulate both transcription and replication; 4 
TopBP1 and Brd4 are cellular proteins that interact with HPV16 E2. Previous work with E2 mutants 5 
demonstrated Brd4 requirement for the transactivation properties of E2 while TopBP1 is required for 6 
DNA replication induced by E2 from the viral origin of replication in association with E1. More recent 7 
studies have also implicated Brd4 in the regulation of DNA replication by E2 and E1. Here we 8 
demonstrate that both TopBP1 and Brd4 are present at the viral origin of replication and that 9 
interaction with E2 is required for optimal initiation of DNA replication. Both cellular proteins are 10 
present in E1-E2 containing nuclear foci and the viral origin of replication is required for the efficient 11 
formation of these foci. shRNA against either TopBP1 or Brd4 destroys the E1-E2 nuclear bodies but has 12 
no effect on E1-E2 mediated levels of DNA replication. An E2 mutation in the context of the complete 13 
HPV16 genome that compromises Brd4 interaction fails to efficiently establish episomes in primary 14 
human keratinocytes. Overall the results suggest that interactions between TopBP1 and E2 and Brd4 15 
and E2 are required to correctly initiate DNA replication but are not required for continuing DNA 16 
replication which may be mediated by alternative processes such as rolling circle amplification and/or 17 
homologous recombination.   18 
Importance 19 
Human papillomavirus 16 is causative in many human cancers including cervical and head and neck and 20 
is responsible for the annual deaths of hundreds of thousands of people worldwide. The current vaccine 21 
will save lives in future generations but anti-virals targeting HPV16 are required for the alleviation of 22 
disease burden on the current, and future, generations. Targeting viral DNA replication that is mediated 23 
3 
 
by two viral proteins E1 and E2 in association with cellular proteins such as TopBP1 and Brd4 would have 1 
therapeutic benefits. This report suggests a role for these cellular proteins in the initiation of viral DNA 2 
replication by HPV16 E1-E2 but not for continuing replication. This is important if viral replication is to 3 
be effectively targeted: we need to understand the viral and cellular proteins required at each phase of 4 
viral DNA replication so that it can be effectively disrupted. 5 
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Introduction 1 
Human papillomaviruses are double stranded DNA viruses that infect the epithelium and cause a variety 2 
of human diseases. HPV16 is the most commonly found HPV in cervical cancer (found in around 50% of 3 
cases) and also in head and neck cancer (around 90% of the HPV positive cases); see (1) for a recent 4 
review. Two viral proteins, E1 and E2, are required for viral replication. E2 has a carboxyl terminus DNA 5 
binding and dimerization domain that binds to 12bp palindromic sequences in the viral genome; 6 
following binding the amino terminal domain of E2 can regulate transcription (2). As well as regulating 7 
transcription the amino terminal domain of E2 can physically associate with E1 to recruit this protein to 8 
the viral origin of replication (3, 4) whereupon E1 forms a di-hexameric complex responsible for 9 
initiating and controlling DNA replication in association with a host of cellular replication factors (5-11). 10 
E2 can also associate with mitotic chromatin via the amino terminal domain while simultaneously 11 
binding to the viral genome; E2 therefore acts as a bridge to attach the viral genome to the host 12 
chromatin during mitosis allowing efficient segregation of the viral genome into daughter cells following 13 
cell division, for a review see (12). A candidate protein for mediating host chromatin attachment for 14 
some E2 proteins is Brd4 (13). Co-localization of HPV16 E2 with the cellular partner protein TopBP1 at 15 
mitosis suggests this protein may also play a role in segregation of the HPV16 genome (14). However, 16 
Brd4 is required for the optimal transcriptional activation and repression properties of all E2 proteins 17 
tested to date (15-34). 18 
The initial role of E2 in DNA replication was proposed to be as an origin recognition complex that bound 19 
to the viral origin of replication and then recruited the viral helicase E1 to the origin (35, 36). More 20 
recently a direct role for E2 recruitment of cellular factors required for DNA replication has been 21 
demonstrated. The cellular protein TopBP1, which can act as a DNA replication factor in eukaryotic cells 22 
(37), is one such factor; failure of E2 to interact optimally with TopBP1 results in compromised DNA 23 
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replication  (38). There have been conflicting reports of the role of Brd4 in regulating the DNA 1 
replication of papillomavirus E2 proteins. In C33a cells HPV16 E2 mutants that have compromised 2 
interaction with Brd4 have compromised replication properties (39, 40) while in CV1 cells mutations in 3 
BPV1 E2 that compromise interaction with Brd4 have no effect on replication (34) although in CHO cells 4 
there was compromised replication (41). In addition, nuclear foci formed by E1 and E2 have Brd4 5 
present in them (39) and mutant HPV16 E2 that fails to bind Brd4 does not enter these nuclear foci (42). 6 
These nuclear foci are considered to be sites of viral DNA replication therefore the presence of Brd4 in 7 
these foci, and the absence of non-Brd4 interacting E2 mutants from them, implicates Brd4 as having a 8 
functional role in DNA replication (39, 42-45). However, the collation of all previous results suggests 9 
some ambiguity in this role and we therefore set out to investigate the role of both TopBP1 and Brd4 in 10 
regulating E1-E2 DNA replication in C33a cells and also to investigate the role for TopBP1 and Brd4 in 11 
maintaining the E1-E2 nuclear foci.  12 
Using a real-time PCR detection method to measure E1-E2 mediated DNA replication (46) results 13 
presented here suggest that both the interactions between HPV16 E2 and Brd4 and TopBP1 are 14 
essential for optimum DNA replication. We also demonstrate the presence of both host proteins at the 15 
viral origin of replication in an E1-E2 dependent manner using chromatin immunoprecipitation. 16 
Immunofluorescence assays demonstrate that HPV16 E1 and E2 form nuclear foci that are in large part 17 
dependent upon the presence of a plasmid containing the viral origin of replication suggesting these are 18 
DNA replication factories. Both TopBP1 and Brd4 can be detected in these replication foci supporting a 19 
role for these cellular proteins in viral DNA replication. shRNA against either TopBP1 or Brd4 completely 20 
destroys the DNA replication foci induced by the expression of E1 and E2 proteins in the presence of the 21 
viral origin but this does not reduce the levels of DNA replication observed. The results suggest that the 22 
initiation of E1-E2 mediated DNA replication in C33a cells requires the presence of both TopBP1 and 23 
Brd4 but that once initiated DNA replication progresses without the involvement of these proteins. 24 
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Experiments with an HPV16 genome containing a mutation in E2 that prevents Brd4 interaction has 1 
compromised ability to establish episomes in primary human keratinocytes, in contrast to previous 2 
experiments with the closely related HPV31 (47). This reveals a difference in the requirements of Brd4 in 3 
the life cycles of HPV16 and HPV31 and further supports the hypothesis that Brd4 is required for 4 
efficient replication of the HPV16 genome. 5 
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Materials and Methods 1 
Cell culture and plasmids. Cells were maintained in Dulbecco’s modified eagle medium (DMEM) with 2 
10% Fetal Calf Serum (FCS) and 1% (v/v) penicillin/streptomycin mixture (Invitrogen Life Technologies) at 3 
37 °C in a 5% CO2/95% air atmosphere. Cells were passaged 1 in 7 every 3 days. The E2 plasmid used is 4 
described in (48) and mutant derivatives prepared as described below in mutagenesis. The pOriM 5 
plasmid used for the replication assays is described in (46) and the ptk6E2-luc plasmid is as used 6 
previously (38). The HA-E1 expression plasmid was a gift from Mart Ustav and is described in (49). The 7 
HPV18LCR was as used previously (38). pshRNA-TopBP1 has been used before by our laboratory (14) and 8 
was originally described in (50). pshRNA-Brd4 was obtained from Addgene and was originally developed 9 
by the Howley lab (17). 10 
Mutagenesis. The R37A Brd4 mutant was prepared as described for our TopBP1 mutant (38) using the 11 
following primers. 5' GACTATTGGAAACACATGGCCCTAGAATGTGCTATTTATTACAAG 3' and 5' 12 
CTTGTAATAAATAGCTCTAACTAGGGCCATGTGTTTCCAATAGTC 3'.  13 
Western blots. Cells were harvested by trypsinization and pelleted by centrifugation. Cell pellets were 14 
washed twice with phosphate buffered saline then re-suspended in 100 µl of lysis buffer (0.5% Nonidet 15 
P-40, 50 mM Tris, pH 7.8, 150 mM NaCl with protease inhibitor cocktail from Roche Molecular 16 
Biochemicals). The cells were lysed on ice for 30 min, and then centrifuged in a refrigerated microfuge 17 
for 10 min at 20,800 rcf at 4 °C. The supernatant was removed to a fresh 1.5 ml tube and the cell debris 18 
discarded. Protein levels were standardized using a BCA Assay (Sigma). Lysates were prepped with 10× 19 
Sample Reducing Agent (Invitrogen) and 5μl 4× LDS Buffer (Invitrogen). The lysates were run on a 4–12% 20 
gradient gel (Invitrogen) at 200 V for 1 h and transferred onto nitrocellulose membranes. Membranes 21 
were blocked in Odyssey blocking buffer (1:1 diluted with PBS) for one hour at room temperature. After 22 
blocking the membranes were incubated with 1:1000 rabbit anti HA-tag antibody to detect E1 (ab9110), 23 
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and 1:5000 (1:1000 for shRNA blot) mouse TVG261 antibody to detect HPV 16E2 (ab17185), overnight at 1 
4°C. Membranes were washed with 0.1% PBS-tween before incubation with Odyssey secondary 2 
antibodies diluted 1:20,000 (Goat anti-mouse IRdye 800cw, 827-08364 and Goat anti-rabbit IRdye 3 
680RD, 926-68171) for one hour at room temperature. Following secondary incubation membranes 4 
were washed 5 times for 5 minutes with 0.01% PBS-tween before infrared scanning using the Odyssey 5 
Li-Cor imaging system. 6 
Transcription activation assay. 2X 105 C33a cells were plated out on a 60-mm plate and transfected 24 h 7 
later using the calcium phosphate technique. The next morning cells were washed with PBS and re-fed 8 
with medium, and 24 h following the wash cells were harvested. The cell monolayers were washed twice 9 
with PBS then lysed with 300 µl reporter lysis buffer (Promega) at room temperature for 10 minutes. 10 
Lysates were harvested by scraping and transferring into a 1.5ml microcentriguge tube and spun in a 11 
refrigerated microfuge for 10 minutes at 4 °C with 3293rcf to clear debris.  80 µl of the supernatant was 12 
assayed for luciferase activity using the luciferase assay system (Promega). To standardise for cell 13 
number a BCA protein assay was carried out and results expressed as luciferase units per µg of protein. 14 
 15 
DNA replication assay. 6×105 C33a cells were seeded in 100-mm2 plates. The following day cells were 16 
CaPO4 transfected with 100 pg of pOriM, 1 μg of E1 and 10ng- 1μg of E2 wild-type and mutant plasmids. 17 
For shRNA replication assays the same transfection process was followed expect for the addition of 1µg 18 
TopBP1 and Brd4 shRNA and control shRNA (plasmids from Addgene). The following morning cells were 19 
washed twice in PBS and re-fed with medium then 48 hours later low molecular weight DNA was 20 
harvested in Hirt solution (10mMEDTA, 0.5%SDS).  Samples were processed for qPCR-detected transient 21 
replication assay as previously described (46). 22 
 23 
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Chromatin Immunoprecipitation. A 100mm2 dish of 60% confluent C33a cells was transfected with 1µg 1 
of pOriM, 1μg of E1 and 10ng- 100ng of E2 wild-type plasmid, using the CaPO4 precipitation method. 2 
The following day cells were washed twice with PBS and transferred to 15cm2 dishes. 48 hours post 3 
transfection cells were cross linked with 1% formaldehyde at room temperature for 15 minutes. The 4 
cross linking reaction was stopped using 0.125M glycine. Cells were harvested by scraping and then 5 
lysed in 1.5X cell pellet volume cell lysis buffer (10 mM Tris-HCl pH 8.0, 10 mM NaCl, 0.2% NP40, 10mM 6 
sodium butyrate, 50 μg/ml PMSF, 1X complete protease inhibitor). Cells were incubated on ice for 10 7 
minutes then nuclei collected by centrifugation at 2500rpm at 4˚c. Cells were then resuspended in 1.2ml 8 
of nuclear lysis buffer (50 mM Tris-HCl pH 8.1, 10 mM EDTA, 1% SDS, 10mM sodium butyrate, 50 μg/ml 9 
PMSF, 1X complete protease inhibitor) and incubated on ice for  a further 10 minutes, then diluted in 10 
0.72ml of immunoprecipitation dilution buffer (IPDB;  20mM Tris-HCl pH 8.1, 150 mM NaCl, 2mM EDTA, 11 
1% Triton X-100, 0.01% SDS, 10mM sodium butyrate, 50 μg/ml PMSF, 1X complete protease inhibitor). 12 
Chromatin was sonicated using a water bath sonicator (Diagenode Bioruptor 300) till chromatin was 13 
sheared to <400bp. Chromatin concentration was measured using a nanodrop and 100µg of chromatin 14 
was used per antibody experiment. The antibodies used were as followed, per IP: 2µl of a sheep anti-15 
HPV16 E2 (amino acids 1-201) prepared and purified by Dundee Cell Products, UK; 2µg of rabbit anti-HA 16 
for detecting HA-E1 (AbCam, ab9110); 2µg rabbit anti-Brd4 (Bethyl, A301-985A1003); 2µg of mouse 17 
anti-TopBP1 (Santa Cruz, sc-271043). The antibodies and chromatin were incubated along with 20µl of a 18 
slurry of A/G magnetic beads (washed in IPDB) (Thermofisher scientific; product number 26162). 19 
Chromatin, bead and antibody slurry was incubated rotated at 4˚c overnight. The following day beads 20 
were washed with 750µl IP wash buffer 1 (x2) (20 mM Tris-HCl pH 8.1, 50 mM NaCl, 2 mM EDTA, 1% 21 
Triton X-100, 0.1% SDS), then with IP wash buffer 2 (x2) (10 mM Tris-HCL pH 8.1, 250 mM LiCl, 1 mM 22 
EDTA, 1% NP-40, 1% deoxycholic acid) and TE pH 8.0 (x1 or x2). Chromatin was then prepared for qPCR 23 
by eluting the immune complexes from the beads by adding 250µl IP elution buffer  (IPEB ; 100 mM 24 
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NaHC03, 1% SDS) and 10µg RNase A; and incubated at 65 ˚C for 30 mins; beads were separated from the 1 
supernatant leaving the ChIP DNA; DNA was incubated for 6 hours to overnight at 65˚C. 100µg of 2 
proteinase K was added following this incubation and incubated for 2 hours at 55 ˚C or overnight at 45 3 
˚C. Taqman qPCR using pOriM primer and probe set was used to quantify the levels of E2, E1, TopBP1 4 
and Brd4 at the HPV origin of replication (46). 5 
Immunofluorescence. Cells were plated at a density of 2 X 105 cells/well on acid-washed coverslips and 6 
simultaneously transfected with the indicated plasmids (Lipofectamine 2000 commercial protocol).  At 7 
24h or 48h post-transfection, cells were fixed in 4% formaldehyde and permeablised with 0.2% Triton X-8 
100. Cells were blocked in 1% FBS and then stained with the indicated primary and secondary 9 
antibodies. Coverslips were mounted in Vectashield mounting medium containing DAPI. Images were 10 
collected with a Zeiss LSM710 laser scanning confocal microscope and analyzed using Zen 2009 LE 11 
software. 12 
Antibodies for immunofluorescence. The following primary antibodies were used in the 13 
immunofluorescence experiments: Ab9110 rabbit anti HA-tag [1:1000] (AbCam), HA.11 mouse anti HA-14 
tag [1:1000] (Covance), mouse anti TopBP1 [1:100] (BD Biosciences), TVG261 mouse anti HPV16 E2 15 
[1:10] (CR-UK), Ab128874 rabbit anti Brd4 [1:500] (AbCam). The following secondary antibodies were 16 
used in the immunofluorescence experiments: Alexa 488 donkey and rabbit [1:1000], Alexa 488 donkey 17 
anti mouse [1:1000], Alexa 555 donkey anti rabbit [1:1000], Alexa 555 donkey anti mouse [1:1000] (all 18 
Life Technologies). 19 
shRNA. Short hairpin RNA (shRNA) against TopBP1 and the appropriate negative control were expressed 20 
from the pBABE-puro plasmid and have been previously described (50). shRNA against Brd4 was 21 
expressed from pSUPER and had the following targeting sequence: GCGGGAGCAGGAGCGAAGA 22 
(Addgene plasmid 24746) (17).  23 
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Life cycle studies. The I73A mutations in the HPV16 and HPV 31 genomes were created using the 1 
QuickChange II Site Directed Mutagenesis kit (Agilent) according to the manufacturer’s directions to 2 
mutagenize the plasmid pEGFP Ni HPV16 or the plasmid pLit HPV31 with the following primers. 16E2 3 
I73A 5’ ATTGTTTCTAACGTTAGTTGCAGTTCAgcTGCTTGTAATGC 3’ and 16E2 I73A 3’ 4 
GCATTACAAGCAgcTGAACTGCAACTAACGTTAGAAACAAT 5’; 31E2 I73A 5’ 5 
GCCAAAGCCTTACAAGCTgcTGAACTACAAATGATGTTGG 3’ and 3’ 6 
CCAACATCATTTGTAGTTCAgcAGCTTGTAAGGCTTTGGC 5’. Wild type and mutant genomes were 7 
transfected into human foreskin keratinocytes (HFK), selected with G418 and expanded in culture to 8 
create cell lines stably maintaining HPV16 or HPV31 as described previously (38, 47). Total DNAs from 9 
HPV16-containing cells were isolated and digested with XhoI, which does not cut the HPV16 genome, or 10 
BamHI, which cuts the HPV16 genome once. Total DNAs from HPV31-containing cells were digested with 11 
XhoI, which does not cut the HPV31 genome, or HindIII, which cuts the HPV31 genome once. Samples 12 
were analyzed by Southern blotting using the whole HPV16 or HPV31 genomes as probes. 13 
  14 
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Results 1 
Transcriptional activation properties of wild type HPV16 E2 and non-Brd4 and non-TopBP1 interacting 2 
mutants in C33a cells 3 
All studies in this report will describe results for HPV16 E2 unless stated otherwise therefore E2 will be 4 
used from this point. Previous work has demonstrated that an R37A mutant (arginine mutated to an 5 
alanine at position 37) in E2 compromises interaction with Brd4, this mutant will be called E2-Brd4 6 
throughout the manuscript (17). Similarly, an N89YE90V mutant is compromised in TopBP1 interaction 7 
and will be called E2-TopBP1 (38). E2-Brd4 is severely compromised in transcriptional activation function (17) 8 
while E2-TopBP1 has altered transcriptional activation properties (38) and to confirm both mutants are 9 
behaving as predicted, transcriptional activation studies were carried out and the results are shown in 10 
Figure 1a. In lanes 1,2,3 it is clear that increasing the levels of E2wt input plasmid increases the 11 
transcriptional levels (as measured by luciferase activity) from the reporter plasmid that contains 6 E2 12 
DNA binding sites located upstream from a tk promoter. As reported previously the fold increase in 13 
transcriptional activation does not mimic the fold increase in plasmid (38). The E2-TopBP1 mutant is 14 
somewhat compromised in transcriptional activation at lower levels but recovers to similar levels to E2wt 15 
at elevated plasmid levels, lanes 4-6, this is similar to results reported previously from 293T cells (38). 16 
E2-Brd4 is severely compromised in the ability to activate transcription at all levels of input plasmid, lanes 17 
7-9, as has been reported previously by others (17). However, there remains a residual ability to activate 18 
transcription at 100ng and 1000ng input levels of plasmid with a fold increase of 2.6 and 2.4 fold 19 
respectively; this may be reflective of a residual interaction with Brd4 for this single point mutant. To 20 
confirm that the mutant proteins retain the ability to repress transcription of a HPV LCR (long control 21 
region) transcriptional assays were carried out and the results shown in Figure 1a. The levels of E2 22 
expression plasmid used are identical as in Figure 1a. In lane 1 the HPV18LCR activity in the absence of 23 
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E2 is set as 1. It is clear that all of the E2 expression plasmids and levels repress transcription from the 1 
LCR again demonstrating that these are functional proteins. The expression levels of the E2 proteins 2 
were also determined in C33a cells following transfection of 1000ng of input plasmid DNA and the 3 
results from this experiment are shown as a western blot in Figure 1c. The upper panel is blotted for E2 4 
and the lower panel for actin, in lane 1 when no E2 expression plasmid is added there is clearly no 5 
detectable E2 protein. In lanes 2-4 E2wt, E2-TopBP1 and E2-Brd4 levels are shown respectively. There is robust 6 
expression of all of these proteins although there is more E2wt than the mutants and this is observed 7 
reproducibly. Overall these results confirm that E2wt, E2-TopBP1 and E2-Brd4 are expressed and behaving as 8 
predicted from previous transcription assays. 9 
DNA replication properties of wild type and non-Brd4 and non-TopBP1 interacting HPV16 E2 mutants in 10 
C33a cells 11 
TopBP1 is a nuclear factor involved in the initiation of DNA replication in eukaryotic systems (37) whose 12 
interaction with E2 is required for optimum DNA replication (38), Brd4 is a chromatin binding protein 13 
with a bromo-domain that can regulate the modification of histones and is involved in regulating E2 14 
transcription function (51). The role of Brd4 in regulating E2 replication properties is less clear. A recent 15 
report demonstrated that there is a 50% drop in replication mediated by an E2-Brd4 mutant (39) while 16 
other reports suggest that Brd4 is not involved in DNA replication by E2 (41). To further investigate 17 
whether Brd4 interaction with E2 is required for E1-E2 mediated DNA replication, assays were carried 18 
out in C33a cells with E2wt, E2-TopBP1 and E2-Brd4 at low and high levels of E2 input plasmid and the levels of 19 
freshly replicated DNA monitored using a sensitive real-time PCR protocol developed in our lab (46). The 20 
results are shown in Figure 2a (10ng E2) and 2b (1000ng E2); our previous work demonstrates that at 21 
10ng E2 input level it is not possible to detect E2 mediated DNA replication by the traditional Southern 22 
blot method therefore the real-time PCR assay allows us to answer questions that cannot be addressed 23 
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by Southern blotting (46). Mock transfected, pOri only (plasmid containing viral origin of replication) and 1 
E1 expression plasmid plus pOri gives very little background signal in these assays (38, 46) therefore only 2 
the results with E2 are presented (the controls are routinely orders of magnitude lower). In Figure 2a the 3 
results are presented on a log scale and E2wt 10ng levels set to 1 and the level of replication induced by 4 
mutants set relative to this. E2-TopBP1 and E2-Brd4 are all severely compromised in DNA replication with 5 
levels of replication being 0.55% and 2.57% of E2wt respectively. Figure 2b describes the results obtained 6 
with 1000ng of E2 levels, our previous studies show that at this level of E2 input we would expect a 7 
recovery of the mutant replication levels compared with E2wt and this is what we observe (38). 8 
Replication levels for E2-TopBP1 and E2-Brd4 at 1000ng of input plasmid are 34.4% and 70.3% respectively 9 
when compared with E2wt. This demonstrates that at higher levels of E2 the failure to initiate replication 10 
is recovered to a large degree in the mutants, perhaps not surprisingly given the elevated levels of E2 11 
mutant proteins that could compensate for replication defects by over expression. We use a log scale in 12 
2a and not in 2b because in 2a the levels of replication are so low that the results would be unclear on a 13 
non-log scale figure. Although these assays clearly rely on over expression of the viral proteins it can be 14 
argued that the lower levels of E2 are more reflective of what occurs in an actual infection. The levels of 15 
replication obtained with the two mutant E2 expression plasmids were very low; to determine if a 16 
double mutant would demonstrate even further reduced levels of DNA replication a double mutant was 17 
prepared that contained the R37A mutation and the N89YE90V mutation; E2-TopBP1/Brd4. In both Figures 2a 18 
and 2b lane 4 it is clear that this double mutant does not further reduce the replication levels of the E2 19 
protein. This suggests that the TopBP1 and Brd4 proteins may somehow be interacting in the same 20 
complex to regulate viral replication and that failure to bind either one of these host proteins 21 
compromises DNA replication almost to the same extent. 22 
TopBP1 and Brd4 locate to the HPV origin of DNA replication in an E1-E2 dependent manner 23 
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The results from Figure 2 suggest that both TopBP1 and Brd4 are required for optimal DNA replication 1 
by the E1-E2 complex predicting that both proteins will be recruited to the origin of replication by E2-E1. 2 
To investigate this chromatin immunoprecipitation (ChIP) assays were carried out with chromatin 3 
prepared from C33a cells that had been transfected with a plasmid containing the HPV16 origin of 4 
replication along with E1 and E2 expression vectors incorporating relevant controls. The results are 5 
presented in Figure 3. Figure 3a shows the results obtained by carrying out the ChIP with an HA antibody 6 
that recognizes the HA-E1 protein. In lane 1 the result with non-transfected cells is shown, lane 2 has 7 
only the origin plasmid transfected while lanes 3 and 4 have the E1 and E2 expression plasmids 8 
transfected respectively; there is no difference in the signal obtained. In lane 5, when pOri plus E1 plus 9 
E2 expression plasmids are transfected then clearly there is an increase in signal of several orders of 10 
magnitude; note the results are presented on a log scale. In Figure 3b the same transfection protocol 11 
was followed through lanes 1-5 and the ChIP carried out with an E2 antibody; again a signal is only 12 
detected when pOri plus E1 plus E2 expression plasmids are transfected. This demonstrates that E2 13 
recruitment and/or stabilization at the origin is facilitated by the presence of E1. Figure 3c shows the 14 
results of the experiment with a TopBP1 antibody where again the signal was only detectable when pOri 15 
plus E1 plus E2 expression plasmids are transfected; Figure 4b demonstrates a similar result for Brd4.  16 
There are several novel findings from these experiments: firstly, E1 and E2 co-operate to interact with 17 
the origin of replication, neither is present in the absence of the other; secondly, TopBP1 is recruited to 18 
the origin of DNA replication in an E1-E2 dependent manner; thirdly, Brd4 is recruited to the origin of 19 
DNA replication in an E1-E2 dependent manner. 20 
TopBP1 and Brd4 are present in E1-E2 induced nuclear foci 21 
Previous results demonstrated that E1 and E2 can locate into nuclear foci when co-expressed and some 22 
reports indicate this is enhanced by the presence of a viral origin while others suggest the presence of 23 
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origin made little difference. E2wt alone or HA E1 alone, plus or minus the viral origin (pOri), could not 1 
form foci (not shown). However, in our hands, E2wt plus HA E1 resulted in the formation of foci that 2 
were greatly enhanced by the presence of the origin. Figure 4a shows a typical examples of randomly 3 
selected fields from an experiment where HA E1, E2 and pOri plasmids were transfected into C33a cells. 4 
The left panel is HA staining (detecting HA E1), the middle panel E2 and the right panel a merge with a 5 
DAPI stained image. There were typically three staining patterns observed; large foci (i), punctate foci (ii) 6 
and a dispersed appearance (iii) that also looked like co-localization was occurring. To determine 7 
whether the presence of pOri influenced the distribution of these foci three independent experiments 8 
were carried out and at least 50 random images captured. The presence of the large, punctate and 9 
diffuse patterns was then counted and the results for E2 shown in Figure 4b and for HA E1 in Figure 4c; 10 
only cells that showed expression of both proteins (the large majority) were scored. Admittedly this type 11 
of quantitation is somewhat subjective (differentiating large from punctate for example) but it is clear 12 
that the presence of pOri resulted in enhanced numbers of large foci containing cells and a reduction of 13 
cells having the dispersed phenotype. This would indicate the large foci are likely replication foci. It is 14 
possible that in the absence of pOri, E1 and E2 form foci that do not increase in size as replication of 15 
pOri does not occur in these foci.  16 
To confirm the presence of TopBP1 and Brd4 in the E1-E2-pOri foci expressing cells were stained for 17 
either TopBP1 or Brd4 and co-stained for E1 as a marker for the replication foci. Representative images 18 
are shown in Figure 5a for TopBP1 and 5b for Brd4; clearly both of these proteins locate, at least 19 
partially, into the replication foci containing E1 and E2. Both proteins in the absence of E1-E2-pOri had a 20 
more dispersed nuclear expression pattern as can be observed in the non-transfected cells shown in 21 
Figure 5a and Figure 5b. 22 
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shRNA against TopBP1 or Brd4 destroys E1-E2-pOri nuclear foci formation but has no effect on E2wt 1 
DNA replication levels. 2 
Next we investigated whether knocking down expression of either TopBP1 or Brd4 would have an effect 3 
on nuclear foci formation and/or E1-E2 mediated DNA replication. We have used the shRNA TopBP1 4 
plasmids previously (14) and demonstrated that it works in C33a cells and the Brd4 shRNA has been 5 
published previously (17). In Figure 6a a typical result with TopBP1 and replication foci staining is shown 6 
following co-transfection with shRNA against TopBP1 or Brd4 as indicated. It is clear in the upper left 7 
panel that in the transfected cell (evidenced by E1 in the upper middle panel) the TopBP1 levels are 8 
reduced relative to the non-transfected cells confirming that the shRNA is working. With both shRNA 9 
treatments there are no replication foci detected, only HA-E1 is stained for but E2 and the pOri plasmids 10 
were co-transfected and there is no TopBP1 detected in foci in any cell.  In Figure 6b a typical result with 11 
Brd4 and replication foci staining is shown following co-transfection with shRNA against TopBP1 (i) or 12 
Brd4 (ii). Again, in the bottom left panel where E2 is being expressed (bottom middle panel) the levels of 13 
Brd4 are reduced confirming that the shRNA is working. With both shRNA treatments there are no 14 
replication foci detected, only HA-E1 is stained for but E2 and the pOri plasmids were co-transfected and 15 
there is no Brd4 detected in foci in any cell. Control shRNA plasmids had no effect on foci formation. 16 
These experiments were carried out several times with identical results and the absence of foci was 17 
observed even after 24 hours. From these results we hypothesized that E1-E2 mediated DNA replication 18 
would be affected and replication assays were carried out at various E2 plasmid concentrations; 19 
10ng,100ng and 1000ng in the presence and absence of shRNA plasmids targeting TopBP1 (Figure 7a) 20 
and Brd4 (Figure 7b). Neither presence of the shRNA against TopBP1/Brd4 nor the control vector had 21 
any statistically significant effect on E1-E2 DNA replication levels at all E2 levels tested; note again that 22 
both Figures have a log scale. To confirm that E1 and E2 protein levels were not affected by the shRNA 23 
treatment, western blots were carried out and the results shown in Figure 7c and 7d. At both 100ng and 24 
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1000ng levels of E2 the shRNA plasmids have no effect on either the E1 or E2 protein levels. E2 is 1 
difficult to detect at 10ng input levels. 2 
HPV16 E2-Brd4 interaction is required for efficient establishment of episomal genomes in primary 3 
human epithelial cells 4 
Previous work with HPV31 demonstrates that a genome encoding a mutant E2 protein that fails to 5 
interact with Brd4, I73A, has no effect on the ability of the genome to maintain episomes (47). The 6 
results presented here demonstrate that for HPV16 E2, wild type interaction with Brd4 is required for 7 
optimum DNA replication. It was therefore hypothesized that there was a difference between HPV16 8 
and HPV31 with regards the requirement of the E2-Brd4 interaction to maintain episomal genomes and 9 
this was tested in primary human foreskin keratinocytes. A comparable mutant of HPV16 E2 that fails to 10 
interact with Brd4, I73A (17, 34), was introduced into the HPV16 genome to allow direct comparison 11 
with the HPV31 genome results (47). Wild type and mutant genomes were transfected into human 12 
foreskin keratinocytes (HFKs) and stable cell lines were cultured following drug selection. We did not 13 
observe any significant defects in the proliferation of cells containing I73A genomes as compared to wild 14 
type (not shown). Southern analysis of total DNAs from wild type cell lines are shown in Figure 8. As 15 
expected uncut DNA from HPV16 wild type cells showed a pattern of bands consistent with episomal 16 
maintenance of the genome, including a small band of supercoiled HPV DNA (upper panel lane 1). 17 
However, in cells containing I73A genomes, in the uncut lane (upper panel lane 3) all of the viral DNA 18 
was found in large, heterogeneous bands consistent with integration of HPV into the host genome, and 19 
no supercoiled band was seen even after long exposure (upper panel lane 5). When linearized, there is 20 
evidence of full length genomes being present (upper panel lanes 4 and 6) but overall there was a vastly 21 
reduced copy number when compared with the HPV16 wild type genome. This demonstrates that the 22 
I73A mutant is compromised in establishing episomal genomes demonstrating the HPV16 E2-Brd 4 23 
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interaction is important for establishing episomes. This was carried out with two independent mutant 1 
HPV16 plasmid clones with identical results. Very similar results were obtained using three independent 2 
sources of foreskin keratinocytes and a total of five experiments overall. By contrast, when the 3 
analogous I73A mutation was created in the context of HPV31 and introduced into HFKs from the same 4 
donors, we found that HPV31 was able to replicate episomally at copy number comparable to wild type 5 
(lower panel), supporting previous results (47). These data indicate that a HPV16 E2 mutant that fails to 6 
bind Brd4 cannot be maintained episomally, and that HPV16 differs from HPV31 in this respect. 7 
  8 
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Discussion 1 
This report presents several novel observations that enhance our understanding of DNA replication by 2 
human papillomavirus 16 E1 and E2. Firstly, the results definitively demonstrate that a mutant of E2 that 3 
is compromised in Brd4 binding has sub-optimal DNA replication properties suggesting that Brd4 is 4 
required for efficient initiation of E1-E2 mediated DNA replication. Secondly, chromatin 5 
immunoprecipitation (ChIP) experiments demonstrate that E1 and E2 go to the viral origin of replication 6 
in a mutually dependent manner. This is novel as it has been proposed that E2 can bind to the origin in 7 
the absence of E1 but this was not observed, it is possible that E1 can stabilize the interaction of E2 with 8 
the origin allowing detection in ChIP assays, much like E1 stabilizes the E2 protein (52). Thirdly, the ChIP 9 
assays demonstrate the presence of TopBP1 and Brd4 at the viral origin of replication in an E1-E2 10 
dependent manner. Fourthly, TopBP1 and Brd4 locate into E1-E2 foci and shRNA targeting the 11 
expression of the cellular proteins destroys these replication foci. Fifthly, E1-E2 DNA replication levels 12 
are not affected by the destruction of the E1-E2 foci therefore replication is not dependent upon these 13 
foci. Sixthly, an E2 Brd4 mutant in the context of the full length HPV16 genome fails to support efficient 14 
establishment of episomal genomes in primary human epithelial cells further supporting a role for Brd4 15 
in mediating HPV16 genome replication in contrast to previous results with HPV31 (47).  16 
There have been reports investigating the role of Brd4 in mediating E2 DNA replication properties, some 17 
supporting a role and some not as described in the introduction. These studies were carried out with 18 
different cell types, different E2 proteins, and different expression vectors and used different assays to 19 
monitor DNA replication. In this report C33a cells were used exclusively and the HPV16 E1 and E2 20 
expression vectors were the same in each assay. It should also be pointed out that the replication assays 21 
that are presented in this paper are extremely sensitive and detect levels not observable on Southern 22 
blots (46). It is notable that at 1000ng of E2 expression plasmid (Figure 2b) there is very little difference 23 
21 
 
between the wild type E2 and E2-Brd4. Therefore previous assays dependent upon the Southern blotting 1 
technique may have failed to detect deficiencies of E2-Brd4 replication due to the limitations of the 2 
technique. The failure of E2-Brd4 to replicate well at low levels (Figure 2a), the localization of Brd4 to the 3 
origin of replication in an E1-E2 dependent manner (Figure 3d), the recruitment of Brd4 to E1-E2 nuclear 4 
foci (Figure 5b), the failure of HPV16 genomes containing an E2-Brd4 mutant to efficiently establish 5 
episomes in primary epithelial cells (Figure 8), all support a role for Brd4 in mediating HPV16 E1-E2 DNA 6 
replication and having an essential role in the viral life cycle. While the mutants are slightly less well 7 
expressed than wild type E2 (Figure 1c) the levels would not explain the drastic reduction in DNA 8 
replication potential (0.5% and 2.5% respectively for the Brd4 and TopBP1 mutants). In addition, at very 9 
low levels of E2 expression plasmid the ability to repress transcription from an HPV LCR is retained 10 
(Figure 1b). Previous results with HPV31 have demonstrated that an E2-Brd4 mutant establishes episomes 11 
as efficiently as wild type HPV31 in primary keratinocytes (47), in contrast to what is observed here for 12 
HPV16. This suggests that there may be differences between the HPV types in their requirement for 13 
Brd4 in genome replication and establishment. This may also explain some of the discrepancies 14 
observed in prior results with different E2 proteins. The results also confirm the role for TopBP1 in 15 
mediating E1-E2 DNA replication (38, 53). Previous work has shown both Brd4 (39) and TopBP1 (43) 16 
recruitment to HPV replication foci further supporting a role for these proteins in this process.Knocking 17 
down either TopBP1 or Brd4 had no effect on E1-E2 mediated DNA replication but completely destroyed 18 
the E1-E2-pOri nuclear foci formation. One interpretation of this result is that neither TopBP1 nor Brd4 19 
are required for DNA replication, but the overwhelming evidence from the results presented here and 20 
by others is that this is not the case. So how can these apparently conflicting observations be reconciled 21 
and do they align with previous observations? One explanation would be that an interaction between 22 
both TopBP1 and Brd4 with E2 is absolutely required for efficient initiation of E1-E2 DNA replication but 23 
that once initiated they are no longer required. In the shRNA experiments presented here E1 and E2 24 
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could be expressed and initiate DNA replication before the elimination of TopBP1 and Brd4. McBride 1 
and colleagues have demonstrated that Brd4 is in the heart of replication foci induced by E1-E2 but after 2 
initiation Brd4 become peripheral to the foci; this would agree with the idea that it is involved in 3 
initiation of replication but not for continuing (54). Recent work from the same group has also 4 
demonstrated association with E2 and Brd4 on similar host regions of chromatin where the viral genome 5 
replicates further suggesting a role for Brd4 in regulating E1-E2 DNA replication (55). E2 also co-localizes 6 
with TopBP1 in late mitosis and this would also associate the viral genome with host proteins that are 7 
involved in DNA replication (14). Our preliminary studies suggest that TopBP1 and Brd4 exist in the same 8 
cellular complex and therefore we propose that the TopBP1-Brd4 complex recruits E2 and the HPV 9 
genomes to locations on host chromatin that promote viral DNA replication following entry into S phase. 10 
Without this co-localization there would be a failure to properly initiate viral DNA replication perhaps 11 
due to mis-localization of the viral genomes to the “wrong” host chromatin locations. Treatment of cells 12 
with JQ1 results in a looser association of Brd4 with chromatin and slightly stimulates E1-E2 mediated 13 
DNA replication (39), this same report supports a role for Brd4 in DNA replication by E1-E2. Therefore 14 
following initiation of DNA replication, dissociation of the Brd4 containing replication complex from the 15 
host chromatin would not reduce replication if Brd4 was only required for correct initiation.  16 
The nuclear foci formed by E1-E2-origin DNA have been proposed as DNA replication factories. This 17 
report demonstrates that both TopBP1 and Brd4 are required for the integrity of these foci as shRNA 18 
against either protein destroys their formation (Figure 5). The results also demonstrate that destruction 19 
of these foci does not affect the levels of E1-E2 DNA replication (Figure 6) suggesting that the foci 20 
induced by E1-E2 are not absolutely required for DNA replication. This is not a timing issue in the 21 
experiments presented as even after 24 hours following transfection the foci are not detected if TopBP1 22 
or Brd4 are knocked down. DNA replication assays are harvested at least 24 hours after this and DNA 23 
replication levels increase during this time (46) therefore if foci are absolutely required for replication a 24 
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reduction in levels would be observed in the experiments presented. It is likely that E1-E2 replication is 1 
initiated prior to the ablation of TopBP1 and Brd4. This raises the question: what are the E1-E2-origin 2 
DNA foci for? There are several possible reasons for the formation of these foci that would promote the 3 
viral life cycle. They may be required for the fidelity of the DNA replication or the decatenation of the 4 
viral genomes following replication allowing faithful replication of viral genomes. They may be formed to 5 
allow the genome to be in open chromatin locations that promote transcription of the viral genome 6 
allowing expression of L1 and L2. They may be required for the encapsidation of the viral genome, 7 
localizing the genomes to distinct cellular locations that will allow efficient packaging. All of these 8 
options require further investigation. 9 
The interpretation of these results would also require the mode of viral DNA replication to switch during 10 
the assays presented. There are three different phases of replication following infection: establishment 11 
that requires initiation of replication and an increase in genome copy number per cell to 20-50; 12 
maintenance where the viral genome copy number per cell is kept steady during the differentiation of 13 
the host cells; and finally amplification where the viral genome increases to around 1000 genome copies 14 
per cell prior to encapsidation and egress. The transient transfection system presented here requires 15 
initiation so therefore mimics at least one aspect of establishment. The presence of the replication foci 16 
that are detected during these transient assays suggest they may also represent the amplification stage 17 
of the life cycle as these foci are only ever seen in differentiated HPV genome containing cells when the 18 
genome is being amplified. It has been proposed that homologous recombination is the mechanism that 19 
HPV uses for amplification of the viral genome during the viral life cycle (44, 56) and the virus can 20 
activate the DNA damage response to promote amplification (57). The results presented here would 21 
support this model; TopBP1 and Brd4 are required for the initiation of DNA replication but would not 22 
necessarily be required for a homologous recombination mechanism of DNA replication although 23 
TopBP1 has been implicated in this process (58, 59).  24 
24 
 
In conclusion, the results presented suggest a role for TopBP1 and Brd4 in the initiation of HPV16 E1-E2 1 
DNA replication but not continuing replication. The results agree with others proposing different modes 2 
of viral DNA replication at different phases of the viral life cycle. Future work should focus on gaining a 3 
better understanding of the cellular and viral proteins required at each stage of the viral life cycle and on 4 
understanding the mechanism of replication at each phase. An added consideration is that there are 5 
perhaps different requirements for DNA replication between HPV high risk types as the results 6 
presented here demonstrate differences in Brd4 requirement for viral episome establishment between 7 
HPV16 and HPV31. Only with a full understanding can viral replication be targeted to assist in the 8 
alleviation of HPV induced disease. 9 
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Legends 
Figure 1. Transcriptional activation properties and expression levels of E2wt, E2-TopBP1, E2-Brd4. a) C33a 
cells were calcium phosphate transfected with 1µg of ptk6E2-luc and the indicated levels of E2 
expression plasmid. Following cell harvest luciferase and protein assays were carried out and the results 
expressed as luciferase units per µg of protein. The figure represents a summary of three independent 
experiments carried out in duplicate; standard error bars are shown. b)  C33a cells were calcium 
phosphate transfected with 1µg of pHPV18LCR-luc and the indicated levels of E2 expression plasmid. 
Following cell harvest luciferase and protein assays were carried out and the results expressed as 
luciferase units per µg of protein. The figure represents a summary of three independent experiments 
carried out in duplicate; standard error bars are shown.c) C33a cells were transfected with 1µg of each 
expression plasmid. Following cell harvest and protein preparation a western blot was carried out with 
50µg of cellular protein extract. Following detection of E2 in the upper panel the membrane was 
stripped and re-probed for actin (lower panel) to ensure equivalent sample loading. 
Figure 2. DNA replication properties of E2wt, E2-TopBP1 and E2-Brd4 in C33a cells. a) C33a cells were 
transfected with 1pg of pOri plasmid, 1000ng of HA-E1 and 10ng of each of the E2 expression vectors. 
Low molecular weight DNA was harvested from the cells and fresh replication assayed as described (46). 
Please note that this Figure uses a log scale. b) C33a cells were transfected with 1pg of pOri plasmid, 
1000ng of HA-E1 and 1000ng of each of the E2 expression vectors. Low molecular weight DNA was 
harvested from the cells and fresh replication assayed as described (46). Please note that this Figure 
does not use a log scale. In both a) and b) the results represent the summary of at least three 
independent experiments and standard error bars are shown. 
Figure 3. TopBP1 and Brd4 are recruited to the viral origin of replication in an E1-E2 dependent 
manner. C33a cells were transfected with nothing (lane 1); 1µg pOri by itself (lane 2); 1µg pOri plus 1µg 
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HA-E1 expression plasmid (lane 3); 1µg pOri plus 1µg E2 expression plasmid (lane 4); 1µg pOri plus 1µg 
HA-E1 expression plasmid plus 1µg of E2 expression plasmid (lane 5). Following cell harvest chromatin 
was prepared and immunoprecipitation experiments carried out with the following antibodies a) HA 
(recognizes E1) b) E2 c) TopBP1 and d) Brd4. Protocols and antibody amounts are described in materials 
and methods. The results presented are the summary of at least three independent experiments and 
the standard error bars are shown. Please note that all Figures use a log scale demonstrating orders of 
magnitude difference between background and the positive signal in lane 5 of each Figure.  
Figure 4. Localization of E1 and E2 into nuclear foci. a) C33a cells were transfected with 1µg pOri, 1µg 
HA E1, 1µg E2 and this panel shows examples of the three types of staining observed: i) Large; ii) 
Punctate; iii) dispersed. HA E1 or E2 by themselves did not form foci and showed a dispersed nuclear 
appearance (not shown). b)  Cells staining positive for both E1 and E2 were scored for the types of cell 
staining observed for E2 in both the absence and presence of pOri. The figure represents the summary 
of at least three experiments with standard error bars shown. c) Cells staining positive for both E1 and 
E2 were scored for the types of cell staining observed for HA E1 in both the absence and presence of 
pOri. The figure represents the summary of at least three experiments with standard error bars shown. 
Figure 5. TopBP1 and Brd4 are recruited to E1-E2 foci. a) C33a cells were transfected with 1µg pOri, 1µg 
HA E1, 1µg E2 then stained for TopBP1 (left panel) or HA (to detect HA E1, middle panel); the presence 
of E1 foci indicated co-expression of E2. Staining is shown in the context of DAPI staining (right panel). 
All cells with E1 foci demonstrated recruitment of TopBP1 to these foci, two example panels are shown. 
b) C33a cells were transfected with 1µg pOri, 1µg HA E1, 1µg E2 then stained for Brd4 (left panels) or HA 
(to detect HA E1, middle panels); the presence of E1 foci indicated co-expression of E2. Staining is shown 
in the context of DAPI staining (right panels). All cells with E1 foci demonstrated recruitment of Brd4 to 
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these foci, two example panels are shown. This experiment was repeated with identical results at least 
three times. 
Figure 6. Knock down of TopBP1 and Brd4 disrupts E1-E2 DNA replication foci. a) C33a cells were 
transfected with 1µg pOri, 1µg HA E1, 1µg E2 and 1µg of pShTopBP1 (i) or 1µg pShBrd4 (ii) then stained 
for TopBP1 (left panels) or HA (to detect HA E1, middle panels); staining is shown in the context of DAPI 
staining (right panels). b) C33a cells were transfected with 1µg pOri, 1µg HA E1, 1µg E2 and 1µg of 
pShTopBP1 (i) or 1µg pShBrd4 (ii) then stained for Brd4 (left panels) or HA (to detect HA E1, middle 
panels); staining is shown in the context of DAPI staining (right panels). This experiment was carried out 
two times with identical results, the knock down of TopBP1 or Brd4 always ablated the E1-E2-pOri 
induced foci. 
Figure 7. Knocking down TopBP1 or Brd4 as no effect on E1-E2 transient DNA replication. a) C33a cells 
were transfected with 1pg of pOri plasmid, 1000ng of pHA-E1 and the indicated amount of E2 
expression vectors. Lanes 1,4,7 had no co-transfected plasmid; lanes 2,5,8 had 1µg of pshRNA control 
vector and lanes 3,6,9 had 1µg pshRNA TopBP1 (14). Low molecular weight DNA was harvested from the 
cells and replicated DNA assayed as described (46). b) C33a cells were transfected with 1pg of pOri 
plasmid, 1000ng of pHA-E1 and the indicated amount of E2 expression vectors. Lanes 1,4,7 had no co-
transfected plasmid; lanes 2,5,8 had 1µg of pshRNA control vector and lanes 3,6,9 had 1µg pshRNA Brd4 
(REF). Low molecular weight DNA was harvested from the cells and replicated DNA assayed as described 
(46). c) Where indicated in the table, C33a cells were transfected with 1µg of HA-E1, the indicated 
amount of E2 expression plasmid and 1µg of pshRNA Control or pshRNA TopBP1. Cells were then 
harvested and blotted as indicated to the left of each blot. d) Where indicated in the table, C33a cells 
were transfected with 1µg of HA-E1, the indicated amount of E2 expression plasmid and 1µg of pshRNA 
Control or pshRNA Brd4. Cells were then harvested and blotted as indicated to the left of each blot. The 
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DNA replication assays were carried out three times independently and the averages are shown with 
standard error bars.    
Figure 8. HPV16 genomes with defects in E2-Brd4 interaction have reduced capacity for establishing 
episomes. An I73A mutation was introduced into the E2 gene in the context of the entire HPV16 
genome. Wild type and mutant HPV16 and HPV31 were transfected into primary human foreskin 
keratinocytes and the transfected cells selected using G418. Total DNAs were isolated from the cells and 
HPV16 samples treated with Xho1 that does not cut the genome (No cut) or BamH1 which cuts once 
(One cut); HPV31 samples were treated with Xho1 (No cut) and HindIII (One cut). On the upper panel 
there is a darker exposure of the blot shown in lanes 3,4. This result was identical in three different 
primary foreskin keratinocyte samples. 
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